This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Emmerich, J. Search for Related Content PubMed PubMed Citation Articles by Emmerich, J. Social Bookmarking                   What's this?

Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy

University Paris–Descartes, Department of Vascular Medicine and Hypertension and Department of Hematology, Hôpital Européen Georges Pompidou, Paris

Critical limb ischemia (CLI) is a severe disease associated with a high risk of amputation and mortality. In patients who cannot be revascularized, several medical options have been tested, including the use of prostanoids, spinal cord stimulation, and lumbar sympathectomy. None of these treatments has demonstrated a benefit on the amputation rates after 6 months of follow-up; these treatments cannot therefore be recommended for CLI treatment in patients forwhom surgery is not an option. In this setting, gene therapy and cell therapy to stimulate angiogenesis have been tested mainly in phase I and II clinical trials and are reviewed in this article. These studies demonstrated the short-term safety and feasibility of these new approaches, but larger randomized studies remain necessary to demonstrate their clinical benefits and longterm safety.

Key Words: critical limb ischemia • lower extremity wounds • angiogenesis • gene therapy • cell therapy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?